News &amp; Updates

Receipt of mRNA COVID-19 vaccination during pregnancy does not appear to increase the incidence of adverse newborn and early infant outcomes and may even be protective, according to a study.

COVID-19 vax in pregnancy not linked to adverse newborn, early infant outcomes

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

Treatment with nirmatrelvir/ritonavir helps lower the incidence of post-COVID conditions (PCC) in older adults, according to a large study.

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

Brentuximab vedotin fares well for CTCL in real-world study

Interim findings from a prospective real-world study in Poland demonstrated favourable clinical outcomes and a tolerable safety profile for the CD30-directed antibody-drug conjugate brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL).

Brentuximab vedotin fares well for CTCL in real-world study

One BPG dose may be enough to treat syphilis, regardless of HIV status

Three doses of benzathine penicillin G (BPG) are not necessarily better than a single dose in the treatment of early syphilis in individuals with or without HIV infection, as shown in a study.

One BPG dose may be enough to treat syphilis, regardless of HIV status

26 Oct 2023

mRNA-1647 vaccine well tolerated regardless of CMV serostatus

MRNA-1647, Moderna's investigational mRNA-based vaccine against cytomegalovirus (CMV), is well tolerated in healthy adults regardless of CMV serostatus, according to a study presented at IDWeek 2023.

mRNA-1647 vaccine well tolerated regardless of CMV serostatus

Monoclonal antibody helps preserve muscle mass regardless of protein intake

Treatment with bimagrumab appears to prevent muscle loss resulting from inadequate protein intake and increase muscle mass in the setting of enough protein intake, according to data from phase I and IIa studies.

Monoclonal antibody helps preserve muscle mass regardless of protein intake

Niraparib tied to more toxicities than olaparib in ovarian cancer

Use of niraparib appears to contribute to a higher risk of haematological toxicities as compared with olaparib, suggests a study. The most common haematological adverse event is anaemia.

Niraparib tied to more toxicities than olaparib in ovarian cancer

25 Oct 2023

Pooled EAGLE subgroup analyses boost gepotidacin potential for uUTI in females

In a pooled analyses of data from the EAGLE*-2 and EAGLE-3 studies, the investigational, first-in-class, oral, triazaacenaphthylene bactericidal antibiotic gepotidacin showed consistent therapeutic efficacy across key patient subgroups and had an acceptable safety profile in female adults and adolescents with uncomplicated urinary tract infections (uUTI) compared with nitrofurantoin.

Pooled EAGLE subgroup analyses boost gepotidacin potential for uUTI in females

25 Oct 2023

Faster-acting insulin aspart may be safely used in expectant mums with diabetes

Treatment with faster-acting insulin aspart in pregnant women with diabetes appears to have no adverse effect on foetal growth and even leads to fewer episodes of hypoglycaemia, according to the Copenfast trial.

Faster-acting insulin aspart may be safely used in expectant mums with diabetes

Older age, comorbidities drivers of hospitalization for RSV

Advanced age (≥65 years) and comorbidities increase the risk of respiratory syncytial virus (RSV)-associated hospitalization, according to a presentation at IDWeek 2023.

Older age, comorbidities drivers of hospitalization for RSV